U.S. patent application number 12/442132 was filed with the patent office on 2010-01-28 for peroral solid pain killer preparation.
This patent application is currently assigned to KREWEL MEUSELBACH GMBH. Invention is credited to Detlef Schierstedt.
Application Number | 20100021543 12/442132 |
Document ID | / |
Family ID | 38476207 |
Filed Date | 2010-01-28 |
United States Patent
Application |
20100021543 |
Kind Code |
A1 |
Schierstedt; Detlef |
January 28, 2010 |
PERORAL SOLID PAIN KILLER PREPARATION
Abstract
The invention relates to peroral solid analgesic formulations
containing opioids and/or morphine analogues in an effect-retarding
matrix.
Inventors: |
Schierstedt; Detlef; (St.
Augustin, DE) |
Correspondence
Address: |
Clements Bernard PLLC
1901 Roxborough Road, Suite 250
Charlotte
NC
28211
US
|
Assignee: |
KREWEL MEUSELBACH GMBH
Eitorf
DE
|
Family ID: |
38476207 |
Appl. No.: |
12/442132 |
Filed: |
March 27, 2008 |
PCT Filed: |
March 27, 2008 |
PCT NO: |
PCT/EP07/57024 |
371 Date: |
April 23, 2009 |
Current U.S.
Class: |
424/474 ;
424/484; 424/486; 424/488; 514/282 |
Current CPC
Class: |
A61K 9/2009 20130101;
A61P 25/04 20180101; A61K 9/2027 20130101 |
Class at
Publication: |
424/474 ;
424/484; 514/282; 424/486; 424/488 |
International
Class: |
A61K 9/14 20060101
A61K009/14; A61K 31/485 20060101 A61K031/485; A61K 9/28 20060101
A61K009/28; A61P 25/04 20060101 A61P025/04 |
Foreign Application Data
Date |
Code |
Application Number |
Sep 22, 2006 |
DE |
102006044694.1 |
Claims
1. A peroral solid analgesic formulation containing opioids and/or
morphine analogues in an effect-retarding matrix, characterized in
that said matrix includes a framework, solid at room temperature,
of natural and/or synthetic inorganic calcium salts that are
insoluble in water.
2. The formulation according to claim 1, characterized in that said
matrix comprises calcium sulfate and/or calcium phosphates,
especially monocalcium phosphate, dicalcium phosphate and/or
tricalcium phosphate.
3. The formulation according to claim 1, characterized by
comprising the calcium salts in an amount of from 20 to 90% by
weight, especially from 60 to 70% by weight.
4. A peroral solid analgesic formulation containing opioids and/or
morphine analogues in an effect-retarding matrix, characterized in
that said matrix includes linear or branched, saturated, mono- or
polyunsaturated, monovalent or polyvalent, natural or synthetic
fatty acids solid at room temperature and/or their alkaline earth
salts each having from 10 to 30 carbon atoms.
5. The formulation according to claim 4, characterized in that said
matrix is derived from stearic acid, magnesium stearate and/or
calcium arachinate.
6. The formulation according to claim 4, characterized by
comprising the alkaline earth salts or fatty acids respectively in
an amount of from 20 to 90% by weight, especially from 60 to 70% by
weight.
7. The formulation according to claim 1, characterized in that said
matrix comprises the calcium salts and the fatty acid salts and/or
their free fatty acids.
8. The formulation according to claim 7, characterized in that said
matrix comprises from 60 to 70% by weight of the calcium salts and
from 10 to 20% by weight of the fatty acid salts and/or fatty
acids.
9. The formulation according to claim 1, characterized in that said
opioids and/or morphine antagonists are selected from oxycodone,
tramadol, tilidine, morphine, hydromorphone, codeine, hydrocodeine,
levorphanol, methadone, meperidine and/or heroine including their
salts and bases.
10. The formulation according to claim 1, characterized in that
said matrix comprises binders, especially low-viscosity
water-soluble polymers or water-insoluble polymers.
11. The formulation according to claim 1, characterized in that
said matrix contains water-soluble fillers, especially sugars,
sugar alcohols, polyvinyl alcohols and/or pyrrolidone derivatives,
especially polyvinylpyrrolidone, or vinylpyrrolidone/vinyl acetate
copolymer.
12. The formulation according to claim 1, characterized in that the
release rate of said opioids and/or morphine analogues as
determined by the USP paddle method is from 12.5 to 42.5% by weight
after one hour; from 25 to 55% by weight after two hours; from 45
to 75% by weight after four hours; and from 55 to 85% by weight
after six hours.
13. The formulation according to claim 1, characterized by
comprising granules, tablets, especially film tablets, coated
tablets and/or capsules.
14. The formulation according to claim 1, characterized by
comprising cellulose.
15. The formulation according to claim 14, characterized by
comprising cellulose in an amount of from 3 to 30% by weight,
especially from 7 to 13% by weight.
16. The formulation according to claim 14, characterized in that
said cellulose includes non gel-forming microcrystalline
cellulose.
17. The formulation according to claim 1, characterized by
comprising an organic and/or inorganic buffer.
18. The formulation according to claim 17, characterized by
comprising a buffer in an amount of from 1 to 30% by weight,
especially from 2 to 10% by weight.
19. The formulation according to claim 17, characterized by
comprising salts of citric and/or phosphoric acids.
20. The formulation according to claim 19, characterized in that
said buffer is selected from sodium dihydrogenphosphate
(NaH.sub.2PO.sub.4), disodium hydrogenphosphate
(Na.sub.2HPO.sub.4), sodium dihydrogencitrate
(NaC.sub.6H.sub.7O.sub.7), disodium hydrogencitrate
(Na.sub.2C.sub.6H.sub.6O.sub.7), especially sodium phosphate
(Na.sub.3PO.sub.4) or sodium citrate
(Na.sub.3C.sub.6H.sub.5O.sub.7).
21. The formulation according to claim 17, characterized by
comprising oxides, hydroxides and/or carbonates of alkali and/or
alkaline earth metals.
22. The peroral solid analgesic formulation containing opioids
and/or morphine analogues in an effect-retarding matrix according
to claim 1, characterized in that said matrix is surrounded by an
enteric film on part or all of its surface, wherein a
drug-containing layer is additionally coated on the matrix and/or
enteric film.
23. The formulation according to claim 22, characterized in that
said effect-retarding matrix contains from 60 to 70% by weight of
the total amount of active ingredient, and the drug-containing
layer contains from 40 to 30% by weight thereof.
Description
[0001] The invention relates to peroral solid analgesic
formulations containing opioids and/or morphine analogues in an
effect-retarding matrix.
[0002] EP 1 327 446 B1 relates among others to controlled release
pharmaceutical compositions containing oxycodone. Without a
particular definition being needed, oxycodone is known to be a
highly effective analgesic. In EP 1 327 446 B1, oxycodone is
incorporated in a retarding matrix as an example of a highly
effective analgesic, in order that the effect may be sustained in
the patient over an extended period of time. According to this
document, the matrix causing the retarding effect may be any matrix
that yields the in vitro release rates of oxycodone within the
narrow ranges required. Preferably, the matrix is a controlled
release matrix, although normal release matrices may be used with a
coating that controls the release of the active ingredient.
Suitable materials for inclusion in a matrix with controlled
release include [0003] (a) hydrophilic polymers, such as rubbers,
cellulose ethers, acrylic resins and protein-derived materials. Of
these polymers, the cellulose ethers, especially
hydroxyalkylcelluloses and carboxyalkylcelluloses, are preferred.
The oral dosage form may contain from 1% by weight to 80% by weight
of at least one hydrophilic or hydrophobic polymer; [0004] (b)
cleavable or digestible long-chain (C.sub.8-50, especially
C.sub.12-40) substituted or unsubstituted hydrocarbons, such as
fatty acids, fatty alcohols, glyceryl esters of fatty acids,
mineral and vegetable oils and waxes. Hydrocarbons having a melting
point of from 25.degree. C. to 90.degree. C. are preferred. Of
these long-chain hydrocarbon compounds, (aliphatic) fatty alcohols
are preferred. The oral dosage form may contain up to 60% by weight
of at least one cleavable long-chain hydrocarbon; [0005] (c)
polyalkylene glycols. The oral dosage form may contain at least 60%
by weight of a polyalkylene glycol.
[0006] A particularly suitable matrix comprises at least one
water-soluble hydroxyalkylcellulose, at least one aliphatic
C.sub.12-23, preferably C.sub.14-22, alcohol and optionally at
least one polyalkylene glycol.
[0007] Said at least one hydroxyalkylcellulose is preferably a
hydroxy(C.sub.1-6)alkylcellulose, such as hydroxypropylcellulose,
hydroxypropylmethylcellulose and, in particular,
hydroxyethylcellulose. The amount of said at least one
hydroxyalkylcellulose in the present oral dosage form is determined
among others by the exact rate of oxycodone release required.
Preferably, however, the oral dosage form contains from 5% by
weight to 25% by weight, especially from 6.25% by weight to 15% by
weight, of said at least one hydroxyalkylcellulose.
[0008] From EP 0 960 619 B1 and the patent references therein,
further retarding agents for opioids are known. In particular, the
retarding agents described herein are selected from hydrophilic or
hydrophobic polymers, i.e., cellulose derivatives, especially
alkylcelluloses or hydroxyalkylcelluloses having 1 to 6 carbon
atoms in the alkyl or hydroxyalkyl residue.
[0009] WO 01/47497 A2 describes pharmaceutical compositions with
controlled release of tramadole hydrochloride, which is contained
therein in an amount of from 100 to 200 mg. In addition to the
actual active ingredient, this composition includes micronized
fats, alkali salts of phosphoric acid, non-ionic vinylpyrrolidone
polymers, salts of higher fatty acids with alkaline earth metals
and silicon oxides.
[0010] US 2004/0253310 A1 describes a pharmaceutical composition
provided with a coating that is insoluble in aqueous media and has
at least one opening, in which the controlled release of the active
substance is effected by erosion though the opening contained in
the coating.
[0011] DE 696 29 797 T2 also describes controlled release
pharmaceutical compositions that include, in addition to the actual
therapeutically active substance, further pharmaceutically
acceptable ingredients, such as a sodium alginate, a
water-swellable polymer, an edible C.sub.8-C.sub.50 hydrocarbon
derivative having a melting point within a range of from 25.degree.
C. to 90.degree. C., and a divalent salt selected from the group
consisting of an iron salt, a zinc salt, a magnesium salt, an
aluminum salt and a calcium salt as well as mixtures of all the
above.
[0012] In U.S. Pat. No. 3,629,393, tablets with a time-dependent
release of the active ingredient are prepared by blending and
compressing three different types of granules.
[0013] DE 24 04 257 A1 also describes compositions for the retarded
release of the active ingredient contained therein which contain,
in addition to the latter, mainly metal soaps as bulking agents,
polyvinyl acetate as a synthetic resin and cellulose acetate
phthalate as a substance causing the sustained release.
[0014] As compared to the above mentioned prior art, the object of
the present invention is to provide a universally applicable matrix
for opioids and/or morphine analogues in various concentrations and
dosage forms, especially for oxycodone.
[0015] In a first embodiment, the above object is achieved by a
peroral solid analgesic formulation containing opioids and/or
morphine analogues in an effect-retarding matrix, characterized in
that said matrix includes a framework, solid at room temperature,
of natural and/or synthetic inorganic calcium salts that are
insoluble in water.
[0016] By means of the present invention, it is possible to retard
the analgesic effect of the mentioned opioids or morphine analogues
over a period of time, wherein the surrounding matrix need not
necessarily disintegrate upon peroral intake. Said framework, solid
at room temperature, of natural and/or synthetic inorganic calcium
salts that are insoluble in water as contained according to the
invention behaves in a way similar to that of a sponge that slowly
releases the opioid and/or morphine analogue contained therein.
[0017] More preferably within the meaning of the present invention,
any per se known calcium salts that are insoluble in water at room
temperature (25.degree. C.) are suitable within the scope of the
present invention. "Insoluble" within the meaning of the present
invention includes the definition that the salt or compound in
question has a solubility of less than 2% by weight in water at
room temperature (25.degree. C.).
[0018] A particular advantage of the use of frameworks that are
solid at room temperature is their proving to be particularly
stable towards changes of modification when stored.
[0019] More preferably within the meaning of the present invention,
the matrix comprises calcium sulfate and/or calcium phosphates,
especially monocalcium phosphate, dicalcium phosphate and/or
tricalcium phosphate. Accordingly, it is possible within the
meaning of the present invention to employ natural and/or synthetic
inorganic calcium salts insoluble in water. More preferably within
the meaning of the present invention, the amount of inorganic
calcium salts employed in the peroral solid analgesic formulations
is from 20% by weight to .sup.90% by weight, especially from 60% by
weight to 70% by weight. The peroral solid analgesic formulations
according to the invention preferably contain from 1 to 500 mg,
especially from 5 to 40 mg of (at least one of the) opioids and/or
morphine analogues, for example, from 5 to 80 mg of oxycodone,
which also include the corresponding salts thereof in the matrix.
The in vitro release rate of the analgesic formulations is
determined by the so-called USP paddle method at 100 rpm in 900 ml
of aqueous buffer (for example, artificial intestinal solution at
37.degree. C. in the course of several hours). The USP blade
agitator (paddle) method is a blade agitator method as described,
for example, in the U.S. Pharmacopeia XII (1990).
[0020] In accordance with the prior art, the present invention also
relates to the use of the opioids and/or morphine analogues for
substantially reducing the range of daily dosages required for pain
control in about 90% of the patients.
[0021] In combination with the framework, solid at room
temperature, of natural and/or synthetic inorganic calcium salts
that are insoluble in water, the matrix may alternatively or
cumulatively comprise linear or branched, saturated, mono- or
polyunsaturated, monovalent or polyvalent, natural or synthetic
fatty acids solid at room temperature or their alkaline earth salts
each having from 10 to 30 carbon atoms.
[0022] "Fatty acids" within the meaning of the present invention
may optionally include natural or synthetic mixtures having a range
of chain lengths. More preferably within the meaning of the present
invention, the fatty acid residues of the matrix are derived from
stearic acid, especially magnesium stearate and/or calcium
arachinate.
[0023] More preferably within the meaning of the present invention,
the peroral solid analgesic formulation includes the alkaline earth
salts or fatty acids of the mentioned fatty acids in an amount of
from 20 to 90% by weight, especially from 60 to 70% by weight. In
particular, this quantitative information applies for the case
where the mentioned salts are contained as the sole matrix formers
(without calcium salts).
[0024] Alternatively or cumulatively to the fatty acid salts, their
free fatty acids may also be employed as matrix formers as long as
the matrix optionally comprises the above mentioned calcium salts.
The use of fatty acids is per se known from the above mentioned
prior art. However, in the present case, it is particularly
preferred to increase the amount of fatty acids as compared to this
prior art and to use them as matrix formers, so that from 10 to 20%
by weight of the fatty acids and/or fatty acid salts, optionally in
combination with from 60 to 70% by weight of the calcium salts,
form the matrix in the formulations according to the invention. By
analogy, the matrix may also contain from 10 to 20% by weight of
the fatty acids in addition to the fatty acid salts in an amount of
from 60 to 70% by weight.
[0025] In principle, any usual opioids and/or morphine analogues
may be employed. More preferably within the meaning of the present
invention, these are selected from oxycodone, tramadol, tilidine,
morphine, hydromorphone, codeine, hydrocodeine, levorphanol,
methadone, meperidine and/or heroine.
[0026] Optionally, the formulations according to the invention may
also contain per se known morphine antagonists in usual amounts.
For example, the use of naloxone, for example, as naloxone
hydrochloride semihydrate, naltrexone and methyl-naltrexone is
particularly preferred. In addition to the above mentioned
components, the controlled release matrix may optionally contain
suitable amounts of other materials, for example, diluents,
lubricants, water-soluble fillers, binders, granulating aids,
colorants, flavorants and glidants that are usual and known in the
pharmaceutical art. For influencing the release rate, weakly
swellable, especially non-swellable, water-soluble auxiliary agents
are desirable, preferably those selected from the groups of
nonpolymers and polymers.
[0027] More preferably within the meaning of the present invention,
polymers are selected from water-soluble polyvinyl alcohols,
polyether glycols, such as PEG 2000, 3000, 4000, 10000 and
pyrrolidone derivatives, for example, Kollidon.RTM. VA64, or
polyvinylpyrrolidone, such as Kollidon.RTM. 25, 30. More preferred
from the group of water-soluble nonpolymers are sugars, mono- and
disaccharides, such as sucrose, fructose, glucose, and sugar
alcohols, such as sorbitol, xylitol and/or mannitol.
[0028] The formulations according to the invention are
characterized in that the release rate of the opioids and/or
morphine analogues is clearly retarded as compared to a usual
standard formulation. As described above, the release rate of the
opioids and/or morphine analogues is determined by the USP paddle
method in the Examples as well. Accordingly, a formulation is
particularly preferred if the release rate of the opioids in the
buffer corresponding to artificial intestinal solution, for
example, pH 7.2, is
[0029] from 12.5 to 42.5% by weight after one hour;
[0030] from 25 to 55% by weight after two hours;
[0031] from 45 to 75% by weight after four hours; and
[0032] from 55 to 85% by weight after six hours.
[0033] The formulations according to the invention may be in almost
any employable form, for example, as granules, tablets, especially
film tablets, coated tablets and/or capsules.
[0034] In addition to the ingredients described above, the
analgesic formulation may additionally comprise cellulose, because
it has an additional retarding effect on the release of the active
ingredient. Preferred amounts of cellulose are from 3 to 30% by
weight, amounts of from 7 to 13% by weight being particularly
preferred. When the proportions of these ingredients are lower, a
non-satisfactory retarding effect is observed.
[0035] Microcrystalline cellulose, especially Avical.RTM.,
Avicel.RTM., Emcocel.RTM., Heweten.RTM. or Vivapur.RTM., are
correspondingly preferred as retarding agents according to the
invention.
[0036] Further, the analgesic formulation may also include an
organic and/or inorganic buffer, preferably in an amount of from 1
to 30% by weight, more preferably in an amount of from 2 to 10% by
weight. Namely, much like cellulose, buffers have also shown a drug
release retarding effect.
[0037] Of such buffers, the salts of citric and/or phosphoric
acids, preferably sodium dihydrogenphosphate (NaH.sub.2PO.sub.4),
disodium hydrogenphosphate (Na.sub.2HPO.sub.4), sodium
dihydrogencitrate (NaC.sub.6H.sub.7O.sub.7), disodium
hydrogencitrate (Na.sub.2C.sub.6H.sub.6O.sub.7), have proven
particularly favorable, more preferably sodium phosphate
(Na.sub.3PO.sub.4) or sodium citrate
(Na.sub.3C.sub.6H.sub.5O.sub.7). "Salts" as used herein means not
only compounds having the elemental composition stated above, but
also usual hydrates and the various modifications thereof.
[0038] Further, alternatively or cumulatively, oxides, hydroxides
and/or carbonates of alkali and/or alkaline earth metals, for
example, magnesium oxide, may also be employed as buffers.
[0039] Further, it has been surprisingly shown that cellulose and
buffers together have a synergistic effect, since the release is
more retarded when a mixture of the two components is used as
compared to using exclusively one of the two retarding agents.
[0040] In order that the time between the administration and the
onsetting effect of the analgesic should not become too long (with
the enteric layer alone, the active ingredient would be released
only after this layer is dissolved in the small intestine), this
combination of matrix and enteric film is advantageously surrounded
by a drug-containing layer. Upon entering the stomach, this
outermost layer will dissolve immediately and thus provides for an
initial dose of the active ingredient.
[0041] In addition, this kind of tablet structure may be found
particularly useful in cases where the (protonated) active
ingredient has a particularly high solubility in acidic medium.
[0042] Advantageously, in such formulations, the active Ingredient
is distributed in such a way that the effect-retarding matrix
contains from 60 to 70% by weight of the total amount of active
ingredient, and the drug-containing layer contains from 40 to 30%
by weight thereof.
[0043] The enteric film preferably comprises shellac, cellulose
acetate phthalate (CAP) and/or Eudragit.RTM..
EXAMPLES
Example 1
[0044] From 80 mg of tramadole hydrochloride, 355 mg of dicalcium
phosphate dihydrate (coarse powder), 50 mg of Kollidon.RTM. 30 and
70 mg of magnesium stearate, a tablet was prepared by direct
pressing (optionally after wetting/drying and pressing). The total
weight of the tablet was 555 mg.
[0045] The release rates were determined as follows according to
the description:
TABLE-US-00001 Time (hours) tramadole (%) 1 39.05 2 53.18 4 69.50 6
81.42
Example 2
[0046] From 80 mg of tramadole hydrochloride, 325 mg of dicalcium
phosphate dihydrate (fine powder), 10 mg of Kollidon.RTM. 30, 40 mg
of PEG 3000 and 110 mg of magnesium stearate, a tablet was prepared
by direct pressing (optionally after wetting/drying and pressing).
The total weight of the tablet was 565 mg.
[0047] The release rates were determined as follows according to
the description:
TABLE-US-00002 Time (hours) tramadole (%) 1 35.2 2 45.61 4 63.02 6
73.24
Example 3
[0048] From 80 mg of tramadole hydrochloride, 325 mg of dicalcium
phosphate dihydrate (fine powder), 10 mg of Kollidon.RTM. 30, 40 mg
of Karion.RTM. P 300 and 110 mg of magnesium stearate, a tablet was
prepared by direct pressing (optionally after wetting/drying and
pressing). The total weight of the tablet was 565 mg.
[0049] The release rates were determined as follows according to
the description:
TABLE-US-00003 Time (hours) tramadole (%) 1 37.8 2 49.15 4 66.64 6
77.65
Example 4
[0050] From 80 mg of tramadole hydrochloride, 325 mg of dicalcium
phosphate dihydrate (coarse powder), 50 mg of Kollidon.RTM. VA 64
and 100 mg of magnesium stearate, a tablet was prepared by direct
pressing (optionally after wetting/drying and pressing). The total
weight of the tablet was 555 mg.
[0051] The release rates were determined as follows according to
the description:
TABLE-US-00004 Time (hours) tramadole (%) 1 34.21 2 45.90 4 61.37 6
71.27
Example 5
[0052] From 80 mg of tramadole hydrochloride, 325 mg of dicalcium
phosphate dehydrate (coarse powder), 50 mg of Kollidon.RTM. 30 and
70 mg of magnesium stearate, a tablet was prepared by direct
pressing (optionally after wetting/drying and pressing). The total
weight of the tablet was 555 mg.
[0053] The release rates were determined as follows according to
the description:
TABLE-US-00005 Time (hours) tramadole (%) 1 38.68 2 52.97 4 69.45 6
82.20
Example 6
[0054] From 80 mg of tramadole hydrochloride, 355 mg of dicalcium
phosphate dehydrate (coarse powder), 50 mg of Kollidon.RTM. 30 and
70 mg of stearic acid, a tablet was prepared by direct pressing
(optionally after wetting/drying and pressing). The total weight of
the tablet was 555 mg.
[0055] The release rates were determined as follows according to
the description:
TABLE-US-00006 Time (hours) tramadole (%) 1 37.71 2 45.32 4 58.31 6
67.41
Example 7
[0056] From 80 mg of tramadole hydrochloride, 355 mg of calcium
sulfate dihydrate, 50 mg of Kollidon.RTM. 30 and 70 mg of magnesium
stearate, a tablet was prepared by direct pressing (optionally
after wetting/drying and pressing). The total weight of the tablet
was 555 mg.
[0057] The release rates were determined as follows according to
the description:
TABLE-US-00007 Time (hours) tramadole (%) 1 36.41 2 46.61 4 58.36 6
66.43
Example 8
[0058] From 80 mg of oxycodone hydrochloride, 355 mg of dicalcium
phosphate dehydrate (coarse powder), 50 mg of Kollidon.RTM. 30 and
70 mg of magnesium stearate, a tablet was prepared by direct
pressing (optionally after wetting/drying and pressing). The total
weight of the tablet was 555 mg.
Example 9
[0059] From 40 mg of oxycodone hydrochloride, 178 mg of dicalcium
phosphate dihydrate (coarse powder), 25 mg of Kollidon.RTM. 30 and
35 mg of magnesium stearate, a tablet was prepared by direct
pressing (optionally after wetting/drying and pressing). The total
weight of the tablet was 278 mg.
Example 10
[0060] From 20 mg of oxycodone hydrochloride, 192.45 mg of
dicalcium phosphate dihydrate (coarse powder), 27.1 mg of
Kollidon.RTM. 30, 7.95 mg of magnesium stearate and 30 mg of
stearic acid, a tablet was prepared by direct pressing (optionally
after wetting/drying and pressing). The total weight of the tablet
was 277.3 mg.
[0061] The release rates were determined as follows according to
the description:
TABLE-US-00008 Time (hours) oxycodone (%) 1 33.2 2 45.8 4 63.2 6
75.0
Example 11
[0062] From 10 mg of oxycodone hydrochloride, 192.45 mg of
dicalcium phosphate dihydrate (coarse powder), 27.1 mg of
Kollidon.RTM. 30, 7.95 mg of magnesium stearate and 30 mg of
stearic acid, a tablet was prepared by direct pressing (optionally
after wetting/drying and pressing). The total weight of the tablet
was 267.5 mg.
Example 12
[0063] From 40 mg of oxycodone hydrochloride, 177.5 mg of dicalcium
phosphate dehydrate (coarse powder), 25 mg of Kollidon.RTM. 30 and
35 mg of stearic acid, a tablet was prepared by direct pressing
(optionally after wetting/drying and pressing). The total weight of
the tablet was 277.5 mg.
[0064] The release rates were determined as follows according to
the description:
TABLE-US-00009 Time (hours) oxycodone (%) 1 33.1 2 51.0 4 65.2 6
75.1
Example 13
Citrate Buffer
[0065] From 40 mg of oxycodone hydrochloride, 230.0 mg of dicalcium
phosphate dehydrate (coarse powder), 25 mg of Kollidon.RTM. 30, 35
mg of stearic acid and 60 mg of trisodium citrate 5.5-hydrate, a
tablet was prepared by direct pressing (optionally after
wetting/drying and pressing). The total weight of the tablet was
390.0 mg.
Example 14
Phosphate Buffer
[0066] From 40 mg of oxycodone hydrochloride, 230.0 mg of dicalcium
phosphate dehydrate (coarse powder), 25 mg of Kollidon.RTM. 30, 35
mg of stearic acid and 30 mg of disodium hydrogenphosphate
dihydrate, a tablet was prepared by direct pressing (optionally
after wetting/drying and pressing). The total weight of the tablet
was 360.0 mg.
Example 15
Avicel pH 102
[0067] From 40 mg of oxycodone hydrochloride, 230.0 mg of dicalcium
phosphate dehydrate (coarse powder), 25 mg of Kollidon.RTM. 30, 35
mg of stearic acid and 30 mg of Avicel pH 102, a tablet was
prepared by direct pressing (optionally after wetting/drying and
pressing). The total weight of the tablet was 360.0 mg.
Example 16
Phosphate Buffer +Avicel pH 102
[0068] From 40 mg of oxycodone hydrochloride, 230.0 mg of dicalcium
phosphate dehydrate (coarse powder), 25 mg of Kollidon.RTM. 30, 35
mg of stearic acid, 45 mg of Avicel pH 102 and 15 mg of trisodium
phosphate 12-hydrate, a tablet was prepared by direct pressing
(optionally after wetting/drying and pressing). The total weight of
the tablet was 390.0 mg.
[0069] The release rates were determined as follows according to
the description:
TABLE-US-00010 Time (hours) oxycodone (%) 1 28.3 2 41.7 3 54.7 4
64.1 5 71.4 6 77.7 7 82.9 8 87.2
[0070] Example 16 shows that the combination of a microcrystalline
cellulose and a buffer has a substantially more pronounced
retarding effect as compared to the components alone.
* * * * *